李诗良，博士
副教授，硕士生导师
邮箱：shiliangli@ecust.edu.cn
地址：上海市徐汇区梅陇路130号华东理工大学实验18楼516室
教育背景
（1）2011-09 至 2016-06，华东理工大学，药学， 博士（导师：李洪林 教授）
（2）2007-09 至 2011-06，华东理工大学，制药工程，学士（导师：李洪林 教授）
科研与学术工作经历
（1）2019-08 至今，华东理工大学，药学院，副教授
（2）2018-11 至 2019-07，华东理工大学，药学院，特聘副研究员
（3）2016-07 至 2018-10，华东理工大学，博士后（导师：徐玉芳 教授）
研究方向
（1）基于结合热/动力学的药物设计
（2）人工智能药物设计方法开发与应用
个人简介
主要聚焦导致药物临床失败的关键问题如药效不足和安全性差等，通过发展药物设计新方法和新技术，针对危及人民生命健康的重大疾病，开展应用研究，发现多类新型强效的候选药物。取得的成绩：1）自主发展新的药物设计方法及程序5套，获软件版权2项；2）通过开发及使用多策略药物设计方法，针对重大疾病如癌症、糖尿病及自身免疫性疾病相关的重要靶标进行系统性药物设计研究，发现多类骨架新颖的活性化合物和先导结构，参与设计的分子中现已有3个1类和1个2类候选新药完成技术成果转化，其中2个进入临床研究；3）在Protein & Cell, APSB, J. Med. Chem.等专业期刊上发表SCI论文43篇，H指数为12，总他引600多次；包括第一/通讯论文22篇，其中一区论文6篇，二区论文6篇，IF>5的10篇；4）申请发明专利14项，转国际PCT专利5项；中国授权专利4项，其中1件专利在国外6个国家和地区授权；5）主持国家、省部级科研项目5项，包括国自然面上和青年项目、上海市“扬帆”计划、中国博士后面上一等资助等。
承担科研项目
（1）国家自然科学基金委员会，专项项目，82150208，2022-01-01至2024-12-31，280万元，在研，参与
（2）国家自然科学基金委员会，面上项目，82173690，2022-01-01至2025-12-31，55万元，在研，主持
（3）国家自然科学基金委员会，青年科学基金项目，81803437，2019-01-01至2021-12-31，21万元，在研，主持
（4）临港实验室，“求索杰出青年计划”开放课题，LG-QS-202206-02，2022-01 至 2024-12，300万元，在研，主持
（5）上海市科委，青年科技英才扬帆计划，18YF1405100，2018-05 至 2021-04，20万元，结题，主持
（6）科技部，国家“重大新药创制”科技重大专项子课题，2018ZX09711002-001-009，2018-01 至 2020-12，241.07万元，结题，参与
（7）中国博士后科学基金会，面上资助，2016M600290，2016-11 至 2018-07，8万元，结题，主持
代表性论文（第一作者或通讯作者）
（1） Xiong, Rui#; Zhang, Leike#; Li, Shiliang#; Sun, Yuan; Ding, Minyi; Wang, Yong; Zhao, Yongliang; Wu, Yan; Shang, Weijuan; Jiang, Xiaming; Shan, Jiwei; Shen, Zihao; Tong, Yi; Xu, Liuxin; Chen, Yu; Liu, Yingle; Zou, Gang; Lavillete, Dimitri; Zhao, Zhenjiang; Wang, Rui; Zhu, Lili; Xiao, Gengfu; Lan, Ke; Li, Honglin*; Xu, Ke*; Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2, Protein & Cell, 2020, 11(10): 723-739.（封面文章）
（2） Zeng, Fanxun#; Li, Shiliang#; Yang, Guantian#; Luo, Yating#; Qi, Tiantian; Liang, Yingfan; Yang, Tingyuan; Zhang, Letian; Wang, Rui*; Zhu, Lili*; Li, Honglin*; Xu, Xiaoyong* ; Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis., Acta Pharmaceutica Sinica B, 2020, 11(3): 795-809.（封面文章）
（3） Li, Shiliang#; Qin, Chun#; Cui, Shichao#; Xu, Hongling; Wu, Fangshu; Wang, Jiawei; Su, Mingbo; Fang, Xiaoyu; Li, Dan; Jiao, Qian; Zhang, Ming; Xia, Chunmei; Zhu, Lili; Wang, Rui; Li, Jia; Jiang, Hualiang; Zhao, Zhenjiang*; Li, Jingya*; Li, Honglin*; Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes, Journal of Medicinal Chemistry, 2019, 62(5): 2348-2361.（封面文章）
（4） Yuan, Yuan#; Xu, Junpeng#; Jiang, Lei#; Yu, Kangjie; Ge#, Yuanyuan; Li, Mingyang; He, Huan; Niu, Qiqi; Shi, Xiayu; Fan, Linni; Chen, Zhuo; Zhao, Zhenjiang; Li, Shiliang*; Xu, Yufang*; Wang, Zhe*; Li, Honglin*; Discovery, Optimization, and Structure-Activity Relationship Study of Novel and Potent RSK4 Inhibitors as Promising Agents for the Treatment of Esophageal Squamous Cell Carcinoma, Journal of Medicinal Chemistry, 2021, 64(18): 13572-13587.
（5） Li Shiliang#; Xu Hongling#; Cui Shichao#; Wu Fangshu; Zhang Youli; Su Mingbo; Gong Yinghui; Qiu Shaobing; Jiao Qian; Qin Chun; Shan Jiwei; Zhang Ming; Wang Jiawei; Yin Qiao; Xu Minghao; Liu Xiaofeng; Wang Rui; Zhu Lili; Li Jia; Xu Yufang; Jiang Hualiang; Zhao Zhenjiang*; Li Jingya*; Li Honglin*; Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes, Journal of Medicinal Chemistry, 2016, 59(14): 6772-6790.
（6） Li Shiliang#; Zhou Yi#; Lu Weiqiang#; Zhong Ye; Song Wenlong; Liu Kangdong; Huang Jin*; Zhao Zhenjiang; Xu Yufang; Liu Xiaofeng*; Li Honglin ; Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-Based Virtual Screening with the Inhibitor-Constrained Refined Homology Model, Journal of Chemical Information and Modeling, 2011, 51(11): 2939-2947.
（7） Yang Gui Xiang; Ge Song Lan; Wu Yan; Huang Jin; Li Shiliang*; Wang Rui*; Ma Lei *; Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents, European Journal of Medicinal Chemistry, 2018, 156: 206-215.
（8） Li, Shiliang; Cai, Chaoqian; Gong, Jiayu; Liu, Xiaofeng; Li, Honglin*; A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing, Proteins: Structure, Function, and Genetics, 2021, 89(11): 1541-1556.（封面文章）
（9） Wang, Disha; Liu, Wenjun; Shen, Zihao; Jiang, Lei; Wang, Jie; Li, Shiliang*; Li, Honglin*; Deep Learning Based Drug Metabolites Prediction, Frontiers in Pharmacology, 2020, 10: 0-1586.
（10） Luo, Na; Fang, Xiaoyu; Su, Mingbo; Zhang, Xinwen; Li, Dan; Li, Honglin; Li, Shiliang*; Zhao, Zhenjiang*; Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors, Chinese Journal of Chemistry, 2021, 39(1): 115-120.
（11） He Gaoqi; Gong Bojie; Li Jianqiang; Song Yiping; Li Shiliang*; Lu Xingjian *; An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types, Frontiers in Pharmacology, 2018, 9: 0-1463.
（12） Meng Jiajia#; Li Shiliang#; Liu Xiaofeng; Zheng Mingyue; Li Honglin*; RD-Metabolizer: an integrated and reaction types extensive approach to predict metabolic sites and metabolites of drug-like molecules, Chemistry Central Journal, 2017, 11: 0-65.
（13） Li Shiliang#; Luan Guoqin#; Ren Xiaoli#; Song Wenlin; Xu Liuxin; Xu Minghao; Zhu Junsheng; Dong Dong; Diao Yanyan; Liu Xiaofeng; Zhu Lili; Wang Rui; Zhao Zhenjiang*; Xu Yufang*; Li Honglin*; Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity, Scientific Reports, 2015, 5: 0-14836.
（14） Li, Qiannan#; Zhang, Tao#; Li, Shiliang#; Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong, Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin*; Xie, Hua*; Xu, Yufang *; Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR(L858R/T790M/C797S), ACS Medicinal Chemistry Letters, 2019, 10(6): 869-873.
（15） Qiu Che#; Yuan Zhen#; He Zhiyan; Chen Huiwen; Liao Yue; Li Shiliang*; Zhou Wei*; Song Zhongchen*; Lipopolysaccharide Preparation Derived From Porphyromonas gingivalis Induces a Weaker Immuno-Inflammatory Response in BV-2 Microglial Cells Than Escherichia coli by Differentially Activating TLR2/4-Mediated NF-κB/STAT3 Signaling Pathways, Frontiers in Cellular and Infection Microbiology, 2021, 11.